Abstract
Fifteen years ago we discovered activity-dependent neuroprotective protein (ADNP), and showed that it is essential for brain formation/function. Our protein interaction studies identified ADNP as a member of the chromatin remodeling complex, SWI/SNF also associated with alternative splicing of tau and prediction of tauopathy. Recently, we have identified cytoplasmic ADNP interactions with the autophagy regulating microtubule-associated protein 1 light chain 3 (LC3) and with microtubule end-binding (EB) proteins. The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide). Thus, we identified a precise target for ADNP/NAP (davunetide) neuroprotection toward improved drug development.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / genetics
-
Alzheimer Disease / metabolism
-
Alzheimer Disease / pathology
-
Animals
-
Autistic Disorder / drug therapy*
-
Autistic Disorder / genetics
-
Autistic Disorder / metabolism
-
Autistic Disorder / pathology
-
Autophagy / drug effects
-
Cytoskeleton / drug effects*
-
Cytoskeleton / genetics
-
Cytoskeleton / metabolism
-
Cytoskeleton / pathology
-
Drug Discovery*
-
Gene Expression Regulation / drug effects
-
Homeodomain Proteins / genetics
-
Homeodomain Proteins / metabolism*
-
Humans
-
Nerve Tissue Proteins / genetics
-
Nerve Tissue Proteins / metabolism*
-
Neuroprotection / drug effects*
-
Oligopeptides / pharmacology
-
Oligopeptides / therapeutic use
-
Protein Interaction Maps / drug effects
-
Schizophrenia / drug therapy*
-
Schizophrenia / genetics
-
Schizophrenia / metabolism
-
Schizophrenia / pathology
Substances
-
ADNP protein, human
-
Homeodomain Proteins
-
Nerve Tissue Proteins
-
Oligopeptides
-
davunetide